e
enGene Holdings Inc
NASDAQ:ENGN
enGene Holdings Inc
NASDAQ:ENGN
Price:
10.36
USD
-2.45%
Market Cap:
$693.9m
Relative Value
The Relative Value of one ENGN stock under the Base Case scenario is 12.16 USD. Compared to the current market price of 10.36 USD, enGene Holdings Inc is Undervalued by 15%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ENGN
Relative Value
Base Case
12.16
USD
Undervaluation 15%
e
Multiples Across Competitors
ENGN Competitors Multiples
enGene Holdings Inc Competitors
enGene Holdings Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
693.9m USD | 0 | -5.7 | -4.2 | -4.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
405B USD | 6.8 | 172 | 16.6 | 23.6 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 377 | -2 377 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.8B USD | 5.6 | 26.5 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186B USD | 6.3 | 21.8 | 14.8 | 14.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.3B USD | 10.2 | 31.1 | 23.8 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83B USD | 5.8 | 18.4 | 13.9 | 15.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR | 14.2 | 33.5 | 57.5 | 59 | |
| AU |
|
CSL Ltd
ASX:CSL
|
71.4B AUD | 3.2 | 16.5 | 11.4 | 14.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
